AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Kiniksa Pharmaceuticals L... (KNSA)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

19.69

-0.03 (-0.15%)

At close: Feb 20, 2025, 3:59 PM

19.69

0.00%

After-hours: Feb 20, 2025, 04:00 PM EST

undefined% (undefined)

Bid	19.69
Market Cap	1.42B
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-0.12
PE Ratio (ttm)	-164.08
Forward PE	n/a
Analyst	Buy

Ask	20.3
Volume	133,493
Avg. Volume (20D)	456,679
Open	19.63
Previous Close	19.72
Day's Range	19.36 - 19.81
52-Week Range	16.56 - 28.15
Beta	undefined

About KNSA

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclo...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date May 25, 2018

Employees 297

Stock Exchange NASDAQ

Ticker Symbol KNSA

Website https://www.kiniksa.com

Full Company Profile

Analyst Forecast

According to 5 analyst ratings, the average rating for KNSA stock is "Buy." The 12-month stock price forecast is $35, which is an increase of 77.76% from the latest price.

Buy 100.00%

Hold 0.00%

Sell 0.00%

Stock Forecasts

Next Earnings Release

Kiniksa Pharmaceuticals Ltd. is scheduled to release its earnings on Mar 3, 2025, before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

3 months ago

-15.66%

Kiniksa Pharmaceuticals shares are trading lower a... Unlock content with Pro Subscription

7 months ago

+22.91%

Kiniksa Pharmaceuticals shares are trading higher after the company reported better-than-expected Q2 sales results and raised its FY24 net product revenue guidance.

News

3 months ago · seekingalpha.com

Kiniksa Pharmaceuticals International, plc (KNSA) Q3 2024 Earnings Call Transcript

Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA ) Q3 2024 Earnings Conference Call October 29, 2024 8:30 AM ET Company Participants Jonathan Kirshenbaum - Investor Relations Sanj Patel - Chair...

3 months ago · zacks.com

Kiniksa Pharmaceuticals, Ltd. (KNSA) Reports Q3 Loss, Tops Revenue Estimates

Kiniksa Pharmaceuticals, Ltd. (KNSA) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.01.